May 9, 2023 07:36 AM EDTUpdated 08:25 AM

Roche hands Chinese biotech $70M for HER2 drug that can go to the brain

Amber Tong

Senior Editor

Roche is still hunting for next-generation drugs that can hit HER2-positive cancer, and it’s found a Phase I candidate it likes from a Chinese biotech.

The Swiss pharma giant will pay Zion Pharma $70 million in upfront and near-term milestones to get its hands on an oral HER2 tyrosine kinase inhibitor.

HER2, or the human epidermal growth factor receptor 2, is an increasingly popular target for cancer drugmakers, with AstraZeneca, Seagen and many other biotechs betting on new molecules.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

TRENDING NOW

Roche hands Chinese biotech $70M for HER2 drug that can go to the brain

Amber Tong

Senior Editor

To read Endpoints News become a free subscriber

Who pays the most (and least) in biopharma? We crunched median salary data from 175 companies

After gene therapy deaths, Astellas to revisit fatal neuromuscular condition in partnership with biotech startup

Upstream Bio matches first funding round with another $200M to get asthma drug to PhIII

FDA commissioner says drug prices are too high, calls for better evidence generation

4DMT's inhalable gene therapy for cystic fibrosis shows early positive signs in tiny group of patients

The new rules of cancer care: Responding to increasing CMS influence on the oncology landscape

Roche hands Chi­nese biotech $70M for HER2 drug that can go to the brain

Amber Tong

Senior Editor

To read Endpoints News become a free subscriber

Who pays the most (and least) in bio­phar­ma? We crunched me­di­an salary da­ta from 175 com­pa­nies

Af­ter gene ther­a­py deaths, Astel­las to re­vis­it fa­tal neu­ro­mus­cu­lar con­di­tion in part­ner­ship with biotech start­up

Up­stream Bio match­es first fund­ing round with an­oth­er $200M to get asth­ma drug to PhI­II

FDA com­mis­sion­er says drug prices are too high, calls for bet­ter ev­i­dence gen­er­a­tion

4DMT's in­hal­able gene ther­a­py for cys­tic fi­bro­sis shows ear­ly pos­i­tive signs in tiny group of pa­tients

The new rules of can­cer care: Re­spond­ing to in­creas­ing CMS in­flu­ence on the on­col­o­gy land­scape

Roche hands Chinese biotech $70M for HER2 drug that can go to the brain

Who pays the most (and least) in biopharma? We crunched median salary data from 175 companies

After gene therapy deaths, Astellas to revisit fatal neuromuscular condition in partnership with biotech startup

Upstream Bio matches first funding round with another $200M to get asthma drug to PhIII

FDA commissioner says drug prices are too high, calls for better evidence generation

4DMT's inhalable gene therapy for cystic fibrosis shows early positive signs in tiny group of patients

The new rules of cancer care: Responding to increasing CMS influence on the oncology landscape